OncoMatch

OncoMatch/Clinical Trials/NCT07801430

Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC

Is NCT07801430 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for non-small cell lung cancer.

NARecruitingFudan UniversityNCT07801430Data as of Sep 2026Location: China

This multicenter, prospective, randomized clinical trial will enroll adults aged 18 to 75 years with resectable clinical stage I (T1-T2aN0M0) invasive non-small cell lung cancer presenting as a single solid nodule (consolidation-to-tumor ratio 1.0) in the left lung. After intraoperative frozen-section confirmation of invasive non-small cell lung cancer and completion of standard lung resection and systematic mediastinal lymph node dissection, participants will be randomly assigned 1:1 either to undergo station 4L lymph node dissection or to omit station 4L dissection. The primary hypothesis is that omitting station 4L dissection is noninferior to performing it with respect to 3-year disease-free survival. Secondary outcomes include 3-year overall survival, perioperative complications, 90-day mortality, and station 4L nodal metastasis.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Required: Stage I

Demographics

Ages ≤ 75

Prior therapy

Cannot have received: radiation therapy

Previous radiotherapy or chemotherapy for the current lung cancer

Cannot have received: cytotoxic chemotherapy

Previous radiotherapy or chemotherapy for the current lung cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07801430 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior radiation therapy, cytotoxic chemotherapy disqualifies patients from enrollment.

What disease stage is eligible?

Stage I is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify